Benefits
Stimulant/sympathomimetic effects (animal evidence)
Animal studies in dogs and rats showed hordenine produced a positive inotropic effect on the heart, increased systolic and diastolic BP, and increased peripheral blood flow, via indirect adrenergic activity (norepinephrine release). Critical caveat: these effects were short-lived and needed high doses. In the one study that compared routes, horses given 2 mg/kg by mouth showed no change at all, while the same dose injected into a vein caused sweating, doubled heart rate and respiratory distress. Human translation has not been demonstrated.
Weak MAO-B inhibitor (potentiates other PEAs)
Hordenine is a selective substrate for MAO-B with weak inhibitory activity. Theoretical mechanism for potentiating phenylethylamine (PEA) and other monoamines that are MAO-B substrates; combined with PEA in some pre-workouts to extend duration. Not a clinically meaningful MAOI like prescription drugs (selegiline, etc.) — far weaker effect.
No direct lipolytic activity (Haj Ahmed and Carpene 2021)
A laboratory study tested hordenine directly on mouse fat cells and on human abdominal fat tissue and found it does not activate or inhibit lipolysis. Adipocytes were responsive to standard stimulants (isoprenaline, forskolin) and inhibitors (insulin) but unresponsive to hordenine. The conclusion was that hordenine is unlikely to increase lipid mobilization from fat depots. Direct evidence against fat-burner marketing claims.
Indirect adrenergic activity (norepinephrine release)
Hordenine acts as indirect adrenergic agonist by promoting norepinephrine release from sympathetic nerve terminals. Mechanism similar to (but weaker than) tyramine and amphetamines. The picture is not clean: in isolated rat vas deferens hordenine caused no contraction, and those authors concluded it was blocking noradrenaline reuptake rather than releasing it. Any contribution to focus and energy through sympathetic activation is theoretical, and no human trial has measured it.
No established respiratory use
Supplement marketing often repeats that hordenine was used in Traditional Chinese Medicine as 'mao gen' for asthma. That identification does not hold up. The barley material in Chinese medicine is mai ya, germinated barley, and its traditional uses are digestive and for reducing milk supply, not respiratory. Mao gen, or bai mao gen, is a different plant altogether, Imperata rhizome, traditionally used to cool blood and promote urination. Any bronchodilator effect would simply be part of the general sympathomimetic response, and it has not been measured in people. Hordenine is not a treatment for asthma or any other breathing condition, and anyone with asthma should rely on the medicines their doctor prescribes.
Mechanism of action
Indirect adrenergic activity via norepinephrine release
Hordenine, like tyramine and amphetamines, is an indirect-acting sympathomimetic — it promotes release of stored norepinephrine from sympathetic nerve terminals. The mechanism is not fully settled: release from stores is what Hapke observed in intact rats and dogs, but in isolated rat vas deferens hordenine caused no contraction at all, and those authors read it as blocking noradrenaline reuptake rather than releasing it. Neither mechanism appears to involve direct receptor binding (unlike epinephrine). Effects depend on existing sympathetic tone and norepinephrine stores. Tachyphylaxis can develop with repeated use.
Selective MAO-B inhibition (weak)
Selectively inhibits MAO-B isoenzyme over MAO-A. In context of PEA potentiation: PEA is rapidly metabolized by MAO-B; hordenine slows this metabolism. However, hordenine itself is also an MAO-B substrate at low concentrations — making it a 'mixed substrate/inhibitor.' Inhibitory activity is weak relative to selective MAOI drugs.
Crosses blood-brain barrier
This has now been tested rather than assumed. In a laboratory model using pig brain capillary cells, hordenine crossed the barrier quickly. Getting there is the problem: the same study found hordenine is pumped from the bloodstream back into the gut and broken down inside intestinal cells, and its authors concluded that a route other than swallowing would be needed to make use of that brain access. In four volunteers who drank beer, oral hordenine reached free plasma levels of only about 12 to 17 nanomolar, which those authors judged too low to interact directly with the dopamine D2 receptor. CNS effects in humans have not been rigorously characterized via PET imaging or microdialysis studies.
No direct beta-adrenergic agonism in adipocytes
Despite weight loss marketing, hordenine does not bind β-adrenergic receptors directly in adipocytes and cannot stimulate lipolysis directly. Any weight management effect would have to come from indirect sympathetic activation, and no human weight or body composition trial has ever measured that for hordenine.
Clinical trials
Veterinary pharmacology study (Frank M, Weckman TJ, Wood T, Woods WE, Tai CL, Chang SL, Ewing A, Blake JW, Tobin T, Equine Vet J 1990;22(6):437-41, doi:10.1111/j.2042-3306.1990.tb04312.x, PMID 2269269).
Horses given oral and intravenous hordenine. Pharmacokinetics (plasma concentration), behavioral effects, vital signs, and respiratory effects measured.
Intravenous administration caused immediate behavioral changes and significant respiratory distress, but symptoms subsided within 30 minutes. Oral administration produced no change in heart rate, respiratory rate, body temperature or behaviour at the same 2.0 mg/kg dose, consistent with poor oral bioavailability. Oral is the only route a supplement uses, so this is the half of the study that matters most to a supplement user. Pharmacokinetic analysis revealed rapid plasma clearance, with no lasting stimulant or depressive effects post-dosing. Foundational evidence that oral hordenine produces minimal systemic effects.
Animal pharmacology study (Hapke HJ, Strathmann W, Dtsch Tierarztl Wochenschr 1995;102(6):228-32, PMID 8582256). This is a veterinary pharmacology paper in animals, not a human clinical trial.
Dogs and rats given hordenine orally and intravenously. Cardiovascular, gastrointestinal, and CNS effects assessed; isolated tissue experiments to elucidate mechanism.
Hordenine produced positive inotropic effect, increased BP, increased peripheral blood flow, inhibited GI movements. Effects characterized as indirectly acting adrenergic mechanism via norepinephrine release. Critical caveat: effects were short-lived and required high doses to be observed. The same paper also reports two findings the summary left out: hordenine had no effect on the psychomotor behaviour of mice, and in isolated organs and tissues with reduced adrenaline content the effect was very poor. The authors concluded that a measurable increase in the performance of racing horses is quite improbable from the amounts present in feed. Animal findings do not translate directly to human supplement doses.
Laboratory study (Haj Ahmed W, Carpene C 2021. Hordenine does not directly activate triglyceride breakdown in adipocytes but is a MAO interacting agent. Integr Food Nutr Metab 8:1-7, doi:10.15761/IFNM.1000302). This journal is not indexed in PubMed or MEDLINE, so the paper carries no PMID and has not been through that filter.
Mouse fat cells (adipocytes) and human subcutaneous adipose tissue homogenates exposed to hordenine and assessed for lipolytic and antilipolytic responses, plus interaction with monoamine oxidase.
Direct evidence that hordenine does not activate or inhibit lipolysis in adipocytes. Cells were responsive to standard agents (isoprenaline, forskolin, insulin) but unresponsive to hordenine. Confirmed weak MAO interaction (substrate/inhibitor) but no direct fat-cell stimulation. Authors concluded: 'Hordenine consumption cannot likely increase lipid mobilization from fat depots.' Foundational counter-evidence against fat burner marketing claims.